Olivier Demaria
Overview
Explore the profile of Olivier Demaria including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
2310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demaria O, Habif G, Vetizou M, Gauthier L, Remark R, Chiossone L, et al.
Sci Immunol
. 2024 Nov;
9(101):eadp3720.
PMID: 39546590
NK cells offer a promising alternative to T cell therapies in cancer. We evaluated IPH6501, a clinical-stage, tetraspecific NK cell engager (NKCE) armed with a non-alpha IL-2 variant (IL-2v), which...
2.
Fenis A, Demaria O, Gauthier L, Vivier E, Narni-Mancinelli E
Nat Rev Immunol
. 2024 Jan;
24(7):471-486.
PMID: 38273127
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers - antibodies engineered to redirect T cells to recognize and...
3.
Mylonas A, Hawerkamp H, Wang Y, Chen J, Messina F, Demaria O, et al.
JCI Insight
. 2023 Jan;
8(4).
PMID: 36633910
Rosacea is a common chronic inflammatory skin disease with a fluctuating course of excessive inflammation and apparent neovascularization. Microbial dysbiosis with a high density of Bacillus oleronius and increased activity...
4.
Demaria O, Gauthier L, Vetizou M, Alvarez A, Vagne C, Habif G, et al.
Cell Rep Med
. 2022 Oct;
3(10):100783.
PMID: 36260981
Harnessing innate immunity is emerging as a promising therapeutic approach in cancer. We report here the design of tetraspecific molecules engaging natural killer (NK) cell-activating receptors NKp46 and CD16a, the...
5.
Carvelli J, Meziani F, Dellamonica J, Cordier P, Allardet-Servent J, Fraisse M, et al.
Crit Care Med
. 2022 Oct;
50(12):1788-1798.
PMID: 36218354
Objectives: Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19. Design: FOR COVID Elimination (FORCE) was a...
6.
7.
Demaria O, Gauthier L, Debroas G, Vivier E
Eur J Immunol
. 2021 Jun;
51(8):1934-1942.
PMID: 34145579
Immuno-oncology is revolutionizing the treatment of cancers, by inducing the recognition and elimination of tumor cells by the immune system. Recent advances have focused on generating or unleashing tumor antigen-specific...
8.
Carvelli J, Demaria O, Vely F, Batista L, Chouaki Benmansour N, Fares J, et al.
Nature
. 2020 Jul;
588(7836):146-150.
PMID: 32726800
Coronavirus disease 2019 (COVID-19) is a disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in a pandemic. The C5a complement factor and its...
9.
Di Domizio J, Belkhodja C, Chenuet P, Fries A, Murray T, Mondejar P, et al.
Nat Immunol
. 2020 Jul;
21(9):1034-1045.
PMID: 32661363
Skin wounds heal by coordinated induction of inflammation and tissue repair, but the initiating events are poorly defined. Here we uncover a fundamental role of commensal skin microbiota in this...
10.
Demaria O, Carvelli J, Batista L, Thibult M, Morel A, Andre P, et al.
Cell Mol Immunol
. 2020 Jul;
17(9):995-997.
PMID: 32612152
No abstract available.